Breaking News, Collaborations & Alliances

Epizyme, GSK Form Epigenetic Alliance

novel small molecule therapeutics targeting histone methyltransferases (HMTs), an important class of epigenetic enzymes, for the treatment of cancer and other diseases.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Epizyme and GlaxoSmithKline have entered a strategic alliance to develop novel small molecule therapeutics targeting histone methyltransferases (HMTs), an important class of epigenetic enzymes, for the treatment of cancer and other diseases. Epizyme will use its HMT discovery platform, chemical library, and expertise to discover and develop HMT therapeutics against the set of targets to be included in the collaboration. Epizyme will receive an upfront payment of $20 million, as well as resear...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters